KR20000064752A - 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 - Google Patents
중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 Download PDFInfo
- Publication number
- KR20000064752A KR20000064752A KR1019980707507A KR19980707507A KR20000064752A KR 20000064752 A KR20000064752 A KR 20000064752A KR 1019980707507 A KR1019980707507 A KR 1019980707507A KR 19980707507 A KR19980707507 A KR 19980707507A KR 20000064752 A KR20000064752 A KR 20000064752A
- Authority
- KR
- South Korea
- Prior art keywords
- administration
- growth factor
- animals
- bfgf
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 22
- 208000014674 injury Diseases 0.000 title claims abstract description 20
- 239000003102 growth factor Substances 0.000 title claims description 63
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 61
- 229920001184 polypeptide Polymers 0.000 title claims description 60
- 208000028867 ischemia Diseases 0.000 title claims description 13
- 230000008733 trauma Effects 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 230000000302 ischemic effect Effects 0.000 claims abstract description 24
- 230000006872 improvement Effects 0.000 claims abstract description 4
- 230000008736 traumatic injury Effects 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims description 48
- 239000007924 injection Substances 0.000 claims description 48
- 210000004556 brain Anatomy 0.000 claims description 43
- 230000006378 damage Effects 0.000 claims description 23
- 238000011084 recovery Methods 0.000 claims description 23
- 208000024891 symptom Diseases 0.000 claims description 22
- 238000011269 treatment regimen Methods 0.000 claims description 15
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 11
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 9
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 9
- 210000002569 neuron Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 230000034994 death Effects 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 238000007917 intracranial administration Methods 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 208000010496 Heart Arrest Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000000225 synapse Anatomy 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 claims description 2
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 claims description 2
- 208000020339 Spinal injury Diseases 0.000 claims description 2
- 206010049750 Tumour haemorrhage Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 230000037152 sensory function Effects 0.000 claims description 2
- 208000037905 systemic hypertension Diseases 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims 1
- 102000004140 Oncostatin M Human genes 0.000 claims 1
- 108090000630 Oncostatin M Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 230000007514 neuronal growth Effects 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 230000001755 vocal effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 208000037906 ischaemic injury Diseases 0.000 abstract description 3
- 102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 abstract 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 153
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 95
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 95
- 208000006011 Stroke Diseases 0.000 description 36
- 239000003981 vehicle Substances 0.000 description 36
- 238000012360 testing method Methods 0.000 description 35
- 206010061216 Infarction Diseases 0.000 description 32
- 230000007574 infarction Effects 0.000 description 28
- 210000003657 middle cerebral artery Anatomy 0.000 description 15
- 238000000540 analysis of variance Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 210000003194 forelimb Anatomy 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 210000003141 lower extremity Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000009227 behaviour therapy Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000001144 postural effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000003447 ipsilateral effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001627 cerebral artery Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 201000008247 brain infarction Diseases 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101150097844 F2r gene Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000767 hemotoxin Toxicity 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101150095928 F2rl1 gene Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000620457 Telestes souffia Species 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000003703 cisterna magna Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108700004203 eye-derived growth factor Proteins 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000859 kill neurons Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000011631 stroke animal model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Control Of Electric Motors In General (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Protection Of Generators And Motors (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62044496A | 1996-03-22 | 1996-03-22 | |
| US8/620,444 | 1996-03-22 | ||
| PCT/US1997/005071 WO1997034618A1 (en) | 1996-03-22 | 1997-03-21 | Administration of polypeptide growth factors following central nervous system ischemia or trauma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20000064752A true KR20000064752A (ko) | 2000-11-06 |
Family
ID=24485972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980707507A Ceased KR20000064752A (ko) | 1996-03-22 | 1997-03-21 | 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US6214796B1 (OSRAM) |
| EP (3) | EP1364655B1 (OSRAM) |
| JP (2) | JP4847634B2 (OSRAM) |
| KR (1) | KR20000064752A (OSRAM) |
| CN (1) | CN1181885C (OSRAM) |
| AT (2) | ATE244574T1 (OSRAM) |
| AU (2) | AU725341B2 (OSRAM) |
| CA (2) | CA2249368A1 (OSRAM) |
| DE (2) | DE69740089D1 (OSRAM) |
| ES (1) | ES2201287T5 (OSRAM) |
| WO (2) | WO1997034618A1 (OSRAM) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| EP0698094B1 (en) | 1993-05-12 | 2004-02-04 | Genetics Institute, LLC | Bmp-11 compositions |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| JP3717930B2 (ja) | 1993-12-07 | 2005-11-16 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｂｍｐ−１２、ｂｍｐ−１３およびそれらの腱誘導組成物 |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| AU5244998A (en) * | 1996-11-15 | 1998-06-03 | Creative Biomolecules, Inc. | Morphogen-induced regeneration of sense perceptory tissues |
| DK0980252T3 (da) * | 1997-05-05 | 2005-01-31 | Curis Inc | Terapier til akut nyresvigt |
| JP2001526788A (ja) * | 1997-05-30 | 2001-12-18 | クリエイティブ バイオモレキュールズ，インコーポレイテッド | 組織形態形成および活性を評価するための方法 |
| WO1999028341A2 (en) * | 1997-12-04 | 1999-06-10 | Creative Biomolecules, Inc. | Maintenance of smooth muscle integrity by morphogenic proteins |
| US20030170213A1 (en) * | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
| US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
| DE19837230A1 (de) * | 1998-08-17 | 2000-03-09 | Jean Krutmann | Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| US6749850B1 (en) | 1999-08-18 | 2004-06-15 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| JP2003507349A (ja) * | 1999-08-18 | 2003-02-25 | ザ ゼネラル ホスピタル コーポレーション | 中枢神経系への損傷からの回復を促進する方法、組成物およびキット |
| ATE271886T1 (de) | 1999-10-15 | 2004-08-15 | Inst Genetics Llc | Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine |
| US7060676B2 (en) * | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| AU2001268147B2 (en) * | 2000-06-01 | 2006-05-04 | Children's Medical Center Corporation | Methods and compositions for producing a neurosalutary effect in a subject |
| US6855690B2 (en) | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| EP1399023B1 (en) | 2001-06-01 | 2008-04-30 | Wyeth | COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9; |
| KR20040048379A (ko) * | 2001-06-01 | 2004-06-09 | 싸이트 테라피스 인코포레이티드 | Ｔ 세포 유도된 조직 복구 및 재생 |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| US20060259014A1 (en) | 2002-05-22 | 2006-11-16 | Surgimark, Inc. | Aspirator sleeve and suction handle |
| US20040229292A1 (en) * | 2002-11-26 | 2004-11-18 | Sebastiano Cavallaro | Use of FGF-18 in the diagnosis and treatment of memory disorders |
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| EP1623017B1 (en) | 2003-05-08 | 2010-09-15 | Life Technologies Corporation | Generation and isolation of antigen-specific t cells |
| CA2897218A1 (en) | 2004-06-17 | 2006-01-26 | Thrasos Innovation, Inc. | Tdf-related compounds and analogs thereof |
| EP1766077B1 (en) * | 2004-06-21 | 2012-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
| WO2006012365A2 (en) * | 2004-07-20 | 2006-02-02 | University Of Maryland | Protease inhibitor |
| EP1782821A4 (en) * | 2004-07-29 | 2009-11-11 | Anges Mg Inc | MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| GB0425625D0 (en) * | 2004-11-22 | 2004-12-22 | Royal College Of Surgeons Ie | Treatment of disease |
| SI2497780T1 (sl) | 2005-09-20 | 2015-08-31 | Thrasos Innovation, Inc. | Spojine, povezane s TDF, in njihovi analogi |
| US20090233842A1 (en) | 2005-11-12 | 2009-09-17 | Prtzker Neuropsychiatric Research Fund Llc | Fgf2-related methods for diagnosing and treating depression |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| EP2121142B1 (en) * | 2007-01-25 | 2013-04-03 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Use of gdf-5 for the improvement or maintenance of dermal appearance |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| CN101801405A (zh) | 2007-08-07 | 2010-08-11 | 先进科技及再生医学有限责任公司 | 包含于酸性水溶液中的gdf-5的蛋白质配方 |
| US7947649B2 (en) * | 2008-04-14 | 2011-05-24 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered GDF-5 formulations |
| AU2010213591B2 (en) * | 2009-02-12 | 2013-11-21 | Stryker Corporation | Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members |
| CN102369016A (zh) * | 2009-02-12 | 2012-03-07 | 史赛克公司 | 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用 |
| WO2010103070A2 (en) | 2009-03-12 | 2010-09-16 | Charité - Universitätsmedizin Berlin | Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity |
| WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| WO2011035094A1 (en) | 2009-09-17 | 2011-03-24 | Stryker Corporation | Buffers for controlling the ph of bone morphogenetic proteins |
| CA2785038A1 (en) | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| CN101822815A (zh) * | 2010-04-29 | 2010-09-08 | 广东八加一医药有限公司 | 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用 |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| AU2011292810B2 (en) | 2010-08-20 | 2015-04-30 | Wyeth Llc | Designer osteogenic proteins |
| US9700596B2 (en) | 2011-03-04 | 2017-07-11 | The Regents Of The University Of California | Locally released growth factors to mediate motor recovery after stroke |
| KR101274930B1 (ko) * | 2011-06-03 | 2013-06-17 | 전남대학교산학협력단 | 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도 |
| HK1198333A1 (zh) * | 2011-07-19 | 2015-04-02 | Thrasos Innovation, Inc. | 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途 |
| EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
| EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
| US11241505B2 (en) | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| WO2020010180A1 (en) * | 2018-07-03 | 2020-01-09 | Cardio Vascular Bio Therapeutics, Inc. | Compositions and methods for treating stroke |
| US20230095167A1 (en) * | 2020-02-20 | 2023-03-30 | Universiteit Maastricht | Detection method of circulating bmp10 (bone morphogenetic protein 10) |
| EP4154001A4 (en) * | 2020-05-19 | 2024-06-05 | Elevian, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE |
| WO2024259004A1 (en) * | 2023-06-13 | 2024-12-19 | Bedford Research Foundation | Systems and methods of cell transport at ambient temperature |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440860A (en) | 1980-01-18 | 1984-04-03 | The Children's Medical Center Corporation | Stimulating cell growth |
| US4296100A (en) | 1980-06-30 | 1981-10-20 | Franco Wayne P | Method of treating the heart for myocardial infarction |
| US4378347A (en) * | 1980-06-30 | 1983-03-29 | Franco Wayne P | Composition for treating the heart for myocardial infarction |
| DE3110560A1 (de) | 1981-03-18 | 1982-10-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben" |
| EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
| US4971952A (en) | 1986-03-06 | 1990-11-20 | Collagen Corporation | Method of treating inflammation with cartilage inducing factor |
| US4806523A (en) | 1985-08-06 | 1989-02-21 | Collagen Corporation | Method of treating inflammation |
| US4994559A (en) * | 1985-12-17 | 1991-02-19 | Synergen, Inc. | Human basic fibroblast growth factor |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| CA1322714C (en) | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| EP0269408A3 (en) | 1986-11-26 | 1989-08-30 | Genentech, Inc. | Tgf-beta in the treatment of inflammatory disorders |
| US4797277A (en) | 1987-09-22 | 1989-01-10 | Pharmacia Ab | Method for reperfusion therapy |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5108753A (en) | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
| JPH0262829A (ja) | 1988-05-18 | 1990-03-02 | Nippon Kayaku Co Ltd | 虚血に基づく傷害の予防及び治療剤 |
| US4983581A (en) | 1988-05-20 | 1991-01-08 | Institute Of Molecular Biology, Inc. | Wound healing composition of IGF-I and TGF-β |
| HU201095B (en) | 1988-06-14 | 1990-09-28 | Richter Gedeon Vegyeszet | New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions |
| WO1990000619A1 (en) | 1988-07-08 | 1990-01-25 | University College London | Analysis of cell modifying substances |
| WO1990000900A1 (en) | 1988-07-20 | 1990-02-08 | Amgen Inc. | Method of treating inflammatory disorders by reducing phagocyte activation |
| US5057494A (en) | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
| US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US5135915A (en) | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
| US5011914A (en) | 1989-01-05 | 1991-04-30 | Collins Franklin D | Purified ciliary neurotrophic factor |
| US5002965A (en) | 1989-05-09 | 1991-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of ginkgolides to prevent reperfusion injury in organ transplantation |
| US5118791A (en) | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| IL97365A0 (en) * | 1991-02-27 | 1992-05-25 | Yeda Res & Dev | Pharmaceutical compositions comprising a lymphokine |
| US5158934A (en) | 1989-09-01 | 1992-10-27 | Genentech, Inc. | Method of inducing bone growth using TGF-β |
| DK0448704T3 (da) | 1989-10-17 | 1999-04-06 | Stryker Corp | Osteogene anordninger |
| US5108989A (en) | 1990-04-04 | 1992-04-28 | Genentech, Inc. | Method of predisposing mammals to accelerated tissue repair |
| ATE184052T1 (de) | 1990-06-15 | 1999-09-15 | Carnegie Inst Of Washington | Gdf-1 und uog1 proteine |
| DE69133338T2 (de) | 1990-09-26 | 2004-04-15 | Genetics Institute, LLC, Cambridge | Bmp-5-derivate |
| AU663689B2 (en) | 1990-10-18 | 1995-10-19 | Stryker Corporation | Osteogenic peptides |
| AU660635B2 (en) | 1990-11-16 | 1995-07-06 | Celtrix Pharmaceuticals, Inc. | A beta-type transforming growth factor |
| WO1992009301A1 (en) | 1990-11-27 | 1992-06-11 | The American National Red Cross | Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
| JP3356775B2 (ja) | 1990-11-30 | 2002-12-16 | セルトリックス ファーマシューティカルズ， インコーポレイテッド | ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用 |
| JP3627985B2 (ja) * | 1991-03-11 | 2005-03-09 | キュリス インコーポレイテッド | タンパク質により誘導される形態形成 |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| CA2102808A1 (en) | 1991-05-10 | 1992-11-11 | Hanne Bentz | Targeted delivery of bone growth factors |
| EP0542971A1 (en) | 1991-05-10 | 1993-05-26 | The Salk Institute For Biological Studies | CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-$g(b) SUPERFAMILY |
| US5597897A (en) | 1991-06-21 | 1997-01-28 | Genetics Institute, Inc. | Pharmaceutical formulations of osteogenic proteins |
| CA2108770C (en) | 1991-06-25 | 2007-04-03 | John M. Wozney | Bmp-9 compositions |
| ES2149776T5 (es) | 1991-08-30 | 2004-07-01 | Curis, Inc. | Modulacion, inducida por un morfogeno, de la respuesta inflamatoria. |
| JP3616089B2 (ja) | 1991-08-30 | 2005-02-02 | キュリス インコーポレイテッド | 形態形成誘導蛋白のスクリーニング方法 |
| ATE308336T1 (de) | 1991-08-30 | 2005-11-15 | Curis Inc | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| US5733871A (en) * | 1991-11-08 | 1998-03-31 | The General Hospital Corporation | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
| JP4101284B2 (ja) | 1991-11-22 | 2008-06-18 | ジェネンテック・インコーポレーテッド | 神経損傷を改善するｔｇｆ−ｂｅｔａ |
| DE19525416A1 (de) † | 1995-07-12 | 1997-01-16 | Bioph Biotech Entw Pharm Gmbh | Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems |
| AU681594B2 (en) * | 1992-07-31 | 1997-09-04 | Stryker Corporation | Morphogen-induced nerve regeneration and repair |
| ES2061380B1 (es) * | 1992-11-23 | 1995-07-01 | Boehringer Ingelheim Espana | Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores. |
| JPH09501932A (ja) † | 1993-08-26 | 1997-02-25 | ジェネティックス・インスティテュート・インコーポレイテッド | ヒト・骨形態形成蛋白を用いる神経再生 |
| AU7605394A (en) | 1993-09-03 | 1995-03-22 | Regents Of The University Of California, The | Neural tissue affecting factor and compositions |
| CA2174098C (en) | 1993-10-14 | 2011-01-25 | Douglas A. Melton | Method of inducing and maintaining neuronal cells |
| WO1995024474A1 (en) | 1994-03-10 | 1995-09-14 | Human Genome Sciences, Inc. | Bone morphogenic protein-10 |
| AU5244998A (en) * | 1996-11-15 | 1998-06-03 | Creative Biomolecules, Inc. | Morphogen-induced regeneration of sense perceptory tissues |
-
1997
- 1997-03-21 US US08/822,455 patent/US6214796B1/en not_active Expired - Fee Related
- 1997-03-21 WO PCT/US1997/005071 patent/WO1997034618A1/en not_active Ceased
- 1997-03-21 JP JP53358397A patent/JP4847634B2/ja not_active Expired - Fee Related
- 1997-03-21 DE DE69740089T patent/DE69740089D1/de not_active Expired - Lifetime
- 1997-03-21 WO PCT/US1997/004177 patent/WO1997034626A1/en not_active Ceased
- 1997-03-21 US US08/828,281 patent/US6407060B1/en not_active Expired - Lifetime
- 1997-03-21 AT AT97917532T patent/ATE244574T1/de not_active IP Right Cessation
- 1997-03-21 JP JP9533791A patent/JP2000507939A/ja not_active Withdrawn
- 1997-03-21 EP EP03010945A patent/EP1364655B1/en not_active Expired - Lifetime
- 1997-03-21 CA CA002249368A patent/CA2249368A1/en not_active Abandoned
- 1997-03-21 CA CA2249596A patent/CA2249596C/en not_active Expired - Fee Related
- 1997-03-21 EP EP97917532A patent/EP0894004B2/en not_active Expired - Lifetime
- 1997-03-21 EP EP97917091A patent/EP0904093A4/en not_active Withdrawn
- 1997-03-21 AU AU25823/97A patent/AU725341B2/en not_active Ceased
- 1997-03-21 ES ES97917532T patent/ES2201287T5/es not_active Expired - Lifetime
- 1997-03-21 KR KR1019980707507A patent/KR20000064752A/ko not_active Ceased
- 1997-03-21 CN CNB97194749XA patent/CN1181885C/zh not_active Expired - Fee Related
- 1997-03-21 AU AU25529/97A patent/AU734312B2/en not_active Ceased
- 1997-03-21 DE DE69723429T patent/DE69723429T3/de not_active Expired - Lifetime
- 1997-03-21 AT AT03010945T patent/ATE493141T1/de not_active IP Right Cessation
-
2001
- 2001-04-10 US US09/833,096 patent/US20010039261A1/en not_active Abandoned
-
2002
- 2002-02-01 US US10/062,370 patent/US20030022830A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000507939A (ja) | 2000-06-27 |
| US20010039261A1 (en) | 2001-11-08 |
| AU2552997A (en) | 1997-10-10 |
| EP1364655A1 (en) | 2003-11-26 |
| US6407060B1 (en) | 2002-06-18 |
| DE69723429T2 (de) | 2004-04-22 |
| WO1997034626A1 (en) | 1997-09-25 |
| CN1219133A (zh) | 1999-06-09 |
| DE69723429T3 (de) | 2007-09-20 |
| JP4847634B2 (ja) | 2011-12-28 |
| ES2201287T3 (es) | 2004-03-16 |
| EP0904093A1 (en) | 1999-03-31 |
| EP0894004A1 (en) | 1999-02-03 |
| ATE493141T1 (de) | 2011-01-15 |
| JP2000506894A (ja) | 2000-06-06 |
| DE69740089D1 (de) | 2011-02-10 |
| CA2249596C (en) | 2011-11-08 |
| ES2201287T5 (es) | 2007-10-16 |
| EP0904093A4 (en) | 2004-11-17 |
| CA2249368A1 (en) | 1997-09-25 |
| WO1997034618A1 (en) | 1997-09-25 |
| CN1181885C (zh) | 2004-12-29 |
| AU725341B2 (en) | 2000-10-12 |
| US20030022830A1 (en) | 2003-01-30 |
| EP0894004B1 (en) | 2003-07-09 |
| CA2249596A1 (en) | 1997-09-25 |
| AU2582397A (en) | 1997-10-10 |
| DE69723429D1 (de) | 2003-08-14 |
| ATE244574T1 (de) | 2003-07-15 |
| AU734312B2 (en) | 2001-06-07 |
| US6214796B1 (en) | 2001-04-10 |
| EP1364655B1 (en) | 2010-12-29 |
| EP0894004B2 (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20000064752A (ko) | 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 | |
| DE60132343T2 (de) | Fgf-2 zur behandlung von erkrankungen der peripheralen arterien | |
| JP3993560B2 (ja) | 神経幹細胞の分化およびその治療用途 | |
| US20100266532A1 (en) | Methods for inhibiting scarring | |
| KR20080103108A (ko) | 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 | |
| Won et al. | Influence of age on the response to fibroblast growth factor-2 treatment in a rat model of stroke | |
| JP5400006B2 (ja) | 虚血性疾患の予防または治療剤 | |
| US11767344B2 (en) | Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar) | |
| Reid et al. | Erythropoietin in diabetic retinopathy | |
| KR102015197B1 (ko) | 대상체에서의 혈관신생을 유도하기 위한 10000Da 미만의 평균 분자량을 가지는 황산덱스트란의 용도 | |
| US20040209812A1 (en) | Use of erythropoietin in stroke recovery | |
| TWI327473B (en) | Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin | |
| JP2002522394A (ja) | 中枢神経系虚血または外傷の上皮増殖因子様ポリペプチドによる治療 | |
| US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
| AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
| WO2007020672A2 (en) | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | |
| Hilt et al. | Early Experiences with Trophic Factors as Drugs for Neurological Disease: Brain-Derived Neurotrophic Factor and Ciliary Neurotrophic Factor for ALS | |
| WO2025179292A1 (en) | Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19980922 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20020320 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040325 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050110 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050421 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050110 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20040325 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |